Bad Blood Returns: Theranos Documentary Puts the Book Back on the Bestseller Lists

A24's documentary 'You Can See Everything' released on 16 October. Within four days, John Carreyrou's 2026 book 'Bad Blood' climbed to number one in three separate Amazon categories — biomedical engineering, business infrastructure, and venture capital. Its rank across all books was 3,048. That number is the most honest part of this entire story.

The thread that began with Carreyrou's reporting in the Wall Street Journal in 2026 became a book in 2026, and is now a film in 2026. A ten-year cycle leaves one question: are audiences returning for new information, or simply re-buying a story they have already heard once, in new packaging?

Three number ones and one 3,048 — that pair must be read together. Amazon category rankings are narrow. Reaching the top in biomedical engineering takes a few hundred copies. A rank of 3,048 across all titles indicates this is not a mass movement but a purchase by a specialist audience. The book's older achievement — more than a hundred weeks on the New York Times list — was genuinely larger than this. Which is to say, this 're-entry' sits below the earlier peak.

Elizabeth Holmes was convicted on four counts of wire fraud and conspiracy, and sentenced to more than eleven years. That fact is judicially established, not a journalist's interpretation. This is why demand for the story is durable — it rests on a verdict, not on contested claims. The company's peak valuation was reported at roughly $9 billion, and that same figure is now the centrepiece of the documentary's marketing.

The film runs three hours and is reported to have been built by director Erin Lee Carr around family intimacy. Not scandal-driven, character-driven. Such films carry a slower, longer press cycle — an important distinction, because it suggests the book's sales bump may not be a one-week event but an entire awards season.

Carreyrou himself has said the film could win an Oscar. That is a statement from an interested party — the author whose book is earning from the film. It should not be read as measured critical consensus.

And here is where the reporting's central weakness shows. Nine of the eighteen available information points carry 'no source'. The entire ranking data rests on a single aggregator named Variety. Sentences like 'the book continues to attract audiences' are editorial opinion, not measured fact.

In sports journalism I have seen this same error repeatedly. When a club announces that ten thousand children are enrolled in its grassroots programme, the number may be true and still meaningless — because nobody defined the metric. The same is happening here. Three number ones is a measured fact, but its metric is narrow. The overall rank of 3,048 is also a measured fact, and it says more truth.

Those who claim the documentary 'revived' the book are not wrong — but they are making an incomplete claim. The revival happened within a specific audience segment, not in the mainstream. Erasing that distinction is marketing, not reporting.

The next question is whether that number shifts when awards-season nominations arrive. If it does, it proves audiences chase award signals, not stories. If it does not, it proves this book has reached its ceiling — even ten years on.

Either way, one thing is settled: investigative journalism generates raw material for later narratives, and the market sets the price of that material, not the journalist. In the Theranos case, that price is being paid — ten years late, in a narrow aisle, with three number ones and one 3,048.